Kushenin Combined with Adefovir Dipivoxil or Entecavir for Chronic Hepatitis B: A Systematic Review and Meta-Analysis

Table 2

Subgroup analysis on treatment period in patients with CHB treated with KS combined with ADV or ETV.

Outcomes	Trials	Participants	Treatment period	Control group	Trials group	Heterogeneity		RR (95% CI)	P-value
						P	I^2 (%)
Undetectable serum HBV-DNA rate	16	1751	Less than one year	548/848	751/903	0.06	38	1.28 (1.21, 1.36)	<0.00001
	16	1592	One year or more	448/784	588/808	0.02	46	1.28 (1.19, 1.37)	<0.00001
Loss of serum HBeAg rate	13	1425	Less than one year	259/684	454/741	0.66	0	1.62 (1.45, 1.80)	<0.00001
	10	986	One year or more	124/487	222/499	0.98	0	1.74 (1.45, 2.08)	<0.00001
HBeAg seroconversion rate	10	1197	Less than one year	157/590	273/607	0.88	0	1.69 (1.45, 1.97)	<0.00001
	15	1504	One year or more	135/736	308/768	0.99	0	2.18 (1.83, 2.60)	<0.00001
ALT normalization rate	13	1411	Less than one year	509/678	632/733	0.51	0	1.11 (1.06, 1.17)	<0.00001
	13	1334	One year or more	475/659	574/675	0.0006	65	1.14 (1.05, 1.24)	<0.00001

KS: Kushenin; ADV: adefovir dipivoxil; ETV: entecavir; CHB: chronic hepatitis B; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen; ALT: alanine aminotransferase.